Imperan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imperan

Property Description
Active ingredient Metoclopramide hydrochloride
Form Tablet, solution for injection, oral solution
Pharmacological class Prokinetic agent, antiemetic
General Purpose Relief from nausea and vomiting, improved gut motility
Origin Synthetic compound

Defining Imperan: Composition and Identity

Imperan is a prescribed, single-ingredient medicinal product that utilizes Metoclopramide as its active ingredient (often formulated as Metoclopramide hydrochloride). The compound is classified as a synthetic organic chemical. This medication is manufactured in various dosage forms, including tablets for oral administration, as well as sterile solution for injection and oral solution in ampoules for parenteral and liquid routes. Its availability across multiple administration routes is clinically recognized for versatility in treating conditions involving gastrointestinal distress.


What Type of Medicine is Imperan? (Pharmacological Class)

Imperan is definitively classified as both a prokinetic agent and a central Dopamine D2 Receptor Antagonist. Its pharmacological role is dual: it works by increasing gastrointestinal motility stimulation, thereby speeding the movement of contents through the upper digestive tract. Metoclopramide is used to help move food through the stomach and intestines faster. Concurrently, its antiemetic activity is achieved by blocking dopamine receptors in the brain's chemoreceptor trigger zone, the area responsible for triggering the vomiting reflex.


General Purpose and Intended Benefit

Imperan is considered an essential medicine, underscoring its established importance in global public health. The general therapeutic purpose of the medicine is to provide relief from the symptoms of nausea and vomiting and to restore normal functioning to the upper digestive system. By acting both peripherally on the gut and centrally in the brain, the medicine is designed to effectively manage the distress associated with impaired gastrointestinal movement and sickness.

Regulatory References

  1. NIH/MedlinePlus Drug Information
  2. World Health Organization's (WHO) Model List of Essential Medicines

What side effects are possible with Imperan?

Adverse Reactions and Safety Profile

The official safety information for Imperan (Metoclopramide) primarily documents adverse reactions classified across several physiological systems, with particular emphasis on neurological effects.

Category Frequency Classification System-Organ Class Involved
Common Drowsiness, Diarrhoea, Asthenia (fatigue), Depression, Parkinsonism Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders
Uncommon Dystonia, Bradycardia, Hallucinations, Amenorrhea Cardiac Disorders, Endocrine Disorders
Rare Convulsions/Seizures, Confusional State Nervous System Disorders
Not Known Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, Anaphylactic reaction Immune System Disorders, Hepatobiliary Disorders

Serious Adverse Reactions

Metoclopramide’s regulatory profile includes warnings for serious, potentially irreversible neurological reactions. Tardive Dyskinesia (TD) is highlighted in the FDA Boxed Warning as a serious movement disorder whose risk increases with the duration of treatment and total cumulative dose. Neuroleptic Malignant Syndrome (NMS) and Acute Extrapyramidal Symptoms (EPS) are also documented as serious adverse reactions [FDA Labeling, SmPC].

Duration and Population Safety Considerations

The label includes specific safety constraints that treatment for most acute conditions should be strictly limited to a short duration (e.g., 5 days in some regions, or generally not exceeding 12 weeks) to mitigate the risk of TD. Risk of adverse effects is documented as increased in older adults and in patients with renal or hepatic impairment due to reduced drug clearance. Furthermore, the risk of acute extrapyramidal disorders is officially documented as increased in the pediatric population.

Regulatory Safety Summary

The core of the regulatory safety structure centers on the classification of neurological adverse effects, establishing that the potential for serious movement disorders is associated with prolonged exposure. This necessitated the explicit regulatory limitations on the duration of use for the medicine.

Overdose and Emergency Response

Overdose manifestations of Imperan (metoclopramide) are described in regulatory documents primarily by central nervous system (CNS) effects and movement disorders. Documented symptoms include drowsiness, confusion, disorientation, and lethargy. The onset of extrapyramidal reactions (uncontrolled movements) and seizures or convulsions are documented manifestations, with unintentional overdose being specifically reported in infants and children. A serious, life-threatening outcome noted in the official labeling is the hematologic disorder Methemoglobinemia, which has occurred in neonates following overdose.

Immediate action is required if an overdose is suspected. Regulatory guidance states that a poison control center or emergency room should be contacted at once. Urgent medical help must be sought immediately if the individual collapses, has a seizure, experiences trouble breathing, or cannot be awakened.

Treatment is symptomatic and supportive, necessitating continuous monitoring of cardiovascular and respiratory functions. While symptoms are typically self-limiting, often resolving within 24 hours, specific interventions are described in regulatory documents. For instance, methylene blue is indicated for the treatment of Methemoglobinemia, and specific anti-Parkinsonian or anticholinergic drugs may be used for the management of extrapyramidal reactions. Official documentation notes that standard procedures like hemodialysis are not considered an effective method for drug removal.

Therapeutic Uses of Imperan

Imperan: Main Uses and Benefits

Imperan (metoclopramide) is a prescription medication utilized in adult patients for specific gastrointestinal conditions. The drug is indicated for the relief of symptoms associated with diabetic gastroparesis (diabetic gastric stasis). This condition involves delayed gastric emptying and may result in symptoms such as nausea, vomiting, a persistent feeling of fullness after meals, and heartburn.

Additionally, Imperan is approved as a short-term therapeutic option for adults with documented, symptomatic gastroesophageal reflux disease (GERD). It is generally reserved for individuals who have not achieved adequate relief from conventional treatment approaches.

The medication may also be used in clinical settings to prevent nausea and vomiting associated with certain emetogenic cancer chemotherapy regimens or post-operative situations. Imperan has demonstrated a positive effect on increasing the movement of the upper digestive tract to help manage these conditions.


Quick Facts

  • Relief of symptoms associated with diabetic gastroparesis.
  • Short-term management of symptomatic gastroesophageal reflux (GERD) in certain patients.
  • Prevention of nausea and vomiting in specific settings, such as following certain chemotherapy treatments.

Eligibility and Restrictions for Use

Official Population Eligibility for Imperan (Metoclopramide)

Imperan's use is strictly defined by regulatory criteria that determine who is eligible to take the medicine and who is prohibited.

Absolute Contraindications (Prohibited Use)

Imperan must not be used by patients with specific medical conditions, as this is an official prohibition listed in regulatory documentation. These include:

  • Gastrointestinal (GI) hemorrhage, mechanical obstruction, or perforation.
  • Pheochromocytoma (a rare adrenal gland tumor).
  • Epilepsy or a known history of drug-induced Tardive Dyskinesia.
  • Patients concomitantly receiving other medications known to cause extrapyramidal reactions.

Age and Condition Restrictions

Use of the medicine is generally limited to adult patients for its primary labeled indications. Imperan is contraindicated in children under 1 year of age and is typically restricted to short-term, second-line treatment for specific conditions in older children. Special caution is required for elderly patients due to a heightened susceptibility to neurological effects.

Eligibility is restricted in patients with severe renal or hepatic impairment, often necessitating a formal dose reduction as specified in the official labeling to prevent drug accumulation. The medicine is not recommended for women who are breastfeeding, as it is known to be excreted into breast milk. Use during pregnancy is generally reserved only when the expected benefit is determined to justify the potential risk to the fetus.

What should I know about interactions with other medicines?

Imperan (metoclopramide) is formally documented to interact with several medicinal products and substances. Contraindicated combinations strictly include Levodopa and other dopaminergic agonists, due to mutual antagonism of effects. Co-administration with certain Neuroleptics is also restricted because of an increased risk of extrapyramidal reactions (EPRs), as noted in regulatory labeling.

A key pharmacokinetic interaction involves strong CYP2D6 inhibitors (e.g., fluoxetine), which reduce metoclopramide metabolism, resulting in an officially documented increase in its plasma concentration. Metoclopramide enhances the absorption of Paracetamol and Aspirin but decreases the bioavailability of Digoxin. Conversely, metoclopramide increases the exposure of Cyclosporine.

Pharmacodynamic interactions include potentiation of sedative effects with Alcohol and CNS depressants (e.g., morphine derivatives). There is also an additive risk of serotonin syndrome when used with serotonergic drugs. Regulatory requirements state a mandatory minimum interval of 6 hours between administrations to mitigate the risk of adverse neurological effects. Furthermore, the official label notes that clearance is significantly reduced in patients with severe renal or hepatic impairment, leading to a documented risk of accumulation.

Mechanism of Action

Dual Chemical Signaling Modulation

Imperan operates via a dual mechanism that modifies both central and peripheral pathways. In the central nervous system, the drug acts as an antagonist (blocker) on dopamine (D2) receptors located in the chemoreceptor trigger zone (CTZ) of the brain. Inhibition of these receptors alters the CTZ's processing of circulating mediator activity and decreases the signal input that provokes a reflex.

Enhanced Upper Gastrointestinal Movement

Peripherally, the drug engages the enteric nervous system by functioning as an agonist (activator) on serotonin (5-HT4) receptors within the muscle layers of the upper digestive tract. Activation of 5-HT4 receptors increases the local release of acetylcholine. This signaling modification enhances muscle contractions (peristalsis) in the stomach and small intestine, which results in the acceleration of the rate of gastric emptying.

Dosage and Administration Information

Official Administration Guidelines

Imperan (metoclopramide) is administered via oral routes (as tablets, oral solution, or ODT) or parenterally (as an intravenous or intramuscular injection). Dosing schedules and use duration vary depending on the specific clinical indication and condition being treated.

Dosing Schedule and Frequency

Instruction Detail
Standard Oral Dose A typical single dose is 10 mg metoclopramide base.
Chronic Oral Use Dosed four times daily (q.i.d.), 30 minutes before each meal and at bedtime.
Maximum Daily Dose Generally 30 mg/day or 40 mg/day depending on the specific indication.
Minimum Dose Interval A minimal interval of 6 hours must be maintained between any two administrations, even if a dose is rejected.

Procedural and Adjustment Rules

Treatment duration is strictly limited. For long-term adult indications, the total course must not exceed 12 weeks. For acute uses, the maximum treatment duration is typically restricted to 5 days.

In special populations, dose reduction is required to avoid accumulation. Patients with moderate-to-severe renal impairment (creatinine clearance < 60 mL/min) generally initiate therapy at approximately one-half the usual dosage, and a 50% dose reduction is required for severe hepatic impairment. Intravenous doses are administered slowly over at least 1 to 3 minutes to comply with procedural standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Investigation

Research has explored the effects of Imperan. Studies evaluated whether the drug might affect inflammation and pain, focusing on measurements related to symptoms in conditions like osteoarthritis. Basic research continues to explore how the drug may act in the body at a cellular level.


Clinical Trial Outcomes

Clinical research has typically focused on the drug's profile in individuals with moderate to severe osteoarthritis.

Joint Function and Mobility

Studies evaluated measurements related to joint function and mobility in clinical trial participants. Researchers examined changes in mobility scores over 12 weeks, with an extension study evaluating data collected across a period of 24 weeks.

Pain and Symptom Management

Subjective patient-reported pain levels were the primary endpoints in most trials.

  • Studies measured pain scores on the VAS (Visual Analog Scale) as a primary endpoint.
  • Research also collected data on self-reported pain intensity.

Safety and Tolerability Profile

Research has examined the side-effect profile of this drug. The most frequently recorded side effects in the main clinical trials included gastrointestinal discomfort and headache. Studies also recorded data regarding serious side effects across all trials. Some research has compared this drug's profile to that of older treatments.

Combination Therapy Studies

Researchers have investigated the drug's use alongside other established treatments. Studies have explored whether the combination treatment might affect patient quality of life. Clinical trials have typically evaluated continuous use of the drug for a duration of 12 weeks, with research design including evaluation of effects following this duration.

Key Studies & References

  1. Clinical Guideline for the management of Osteoarthritis (Relevant National Society Document)
  2. A comparison of Imperan monotherapy versus combination therapy for chronic pain management: A Phase 3b trial

Frequently Asked Questions (FAQ)

Common questions about Imperan (FAQ)


Q: How quickly does Imperan start to work?

According to official product information, the onset of action after taking an oral dose is documented to begin within 30 to 60 minutes. The pharmacological effects are documented to persist for approximately one to two hours following administration.


Q: Can Imperan be taken long-term?

Regulatory documents strictly restrict the duration of therapy for Imperan. Official guidance states that treatment should generally not exceed 12 weeks due to the potential risk of developing a serious movement disorder known as Tardive Dyskinesia with prolonged use.


Q: Can I stop taking Imperan suddenly?

Regulatory documents do not provide a specific self-instruction for ending treatment. A decision regarding treatment cessation is managed by a qualified healthcare provider, particularly given the risk of neurological effects.


Q: What if I take Imperan, but don't feel any different?

The effects following a single dose are documented to persist for about one to two hours. Symptom relief is expected as short-term therapy progresses.


Q: How long do the effects of Imperan typically last?

The pharmacological effects of a single dose of Imperan are generally documented to last for approximately one to two hours after administration.


Q: Is the effect of Imperan immediate or gradual?

Since the onset of action following an oral dose is documented to begin within 30 to 60 minutes, the effect is considered to be gradual rather than immediate.


Q: Is Imperan a painkiller?

Imperan is classified by regulatory bodies as a prokinetic agent and an antiemetic medicine. Its general therapeutic purpose is for relief from nausea and vomiting and to improve upper digestive system movement.


Q: Does Imperan require regular blood tests?

Regulatory information indicates that patients with insulin-controlled diabetes mellitus may require monitoring of blood glucose concentrations while taking this medicine. The requirement for blood tests is based on specific health conditions.


Q: What should I do if I feel dizzy after taking Imperan?

Dizziness is listed as a common side effect of Imperan. Official sources caution that the medicine may cause sleepiness or drowsiness, which can affect an individual's ability to drive or safely operate machinery.


Q: How is Imperan different from a supplement?

Imperan is a prescription medicine that contains a single, chemically-defined active ingredient called Metoclopramide. It is strictly regulated by government health authorities as a medicinal product for specific, approved uses.


Q: Is it safe to drive while taking Imperan?

Due to the potential for side effects such as drowsiness, tiredness, or dizziness, regulatory documents advise caution regarding driving or operating machinery until the individual is aware of how the medicine affects them.


Q: Can Imperan affect fertility?

Official patient information states that there is no current evidence indicating that Imperan affects fertility.


Q: Is Imperan addictive?

Imperan is not classified as a controlled substance by regulatory bodies. Official warnings for the drug focus on the risk of movement disorders (e.g., Tardive Dyskinesia) with prolonged use, not dependency or addiction.


Q: What kind of research has been done on Imperan?

Clinical research has focused on the drug's approved uses, such as treating diabetic gastroparesis and gastroesophageal reflux disease (GERD). Studies also include its use for specific types of nausea and vomiting, like those related to chemotherapy, radiotherapy, or acute migraine.


Q: What if I accidentally take too much Imperan?

Regulatory sources list potential symptoms of an accidental overdose, which may include drowsiness, confusion, headache, dizziness, agitation, and uncontrolled spasm of muscles.


Q: Does Imperan cause skin rash or itching?

While skin rash or itching is not listed as a common side effect, the official label does include the potential for serious, yet rare, immune system reactions like anaphylaxis. Symptoms of such a reaction can involve a rash, swelling, or blistering of the skin.


Q: How long does Imperan stay in your system?

The average elimination half-life of the active ingredient is documented to be 5 to 6 hours in individuals with normal kidney function. The half-life is the time it takes for half of the dose to be removed from the body.


Q: Is there a generic version of Imperan available?

Yes, regulatory and official sources confirm that a lower-cost generic version of the medicine, which contains the active ingredient Metoclopramide, is available.


Q: What if I already have other side effects from other medications?

Regulatory warnings highlight that taking Imperan alongside certain other medications carries an officially documented additive risk for serious side effects. For example, the risk of extrapyramidal reactions or serotonin syndrome is increased when used with specific classes of drugs.


Q: Is Imperan part of a wider treatment plan?

Official research has explored Imperan's use in combination therapy alongside other established treatments. Furthermore, for some conditions, regulatory documents indicate that the medicine is reserved for patients who have not responded adequately to conventional therapies.


Q: Who was Imperan originally developed for?

The active ingredient in Imperan was first approved by regulatory authorities in Japan in 1967. The initial intended uses focused on the decrease in appetite and the general treatment of nausea and vomiting.


Q: Is Imperan considered a high-risk medication?

Regulatory agencies have issued warnings, including an FDA Boxed Warning, and have restricted the allowed dose and duration of use. These limitations are put in place to help minimize the risk of potentially serious neurological adverse effects, such as Tardive Dyskinesia.


Q: What happens if I miss a dose of Imperan?

Regulatory guidance for a missed dose recommends that the individual skip the forgotten dose and take the next dose at the usual time. It is crucial to ensure that a minimum interval of 6 hours is maintained between any two administrations.


Q: Is Imperan used to treat more than one condition?

Yes, regulatory documents list multiple approved indications. These include the short-term treatment of symptomatic gastroesophageal reflux disease (GERD), diabetic gastroparesis, and the prevention and treatment of various types of nausea and vomiting.

How should Imperan be stored and disposed of?

Official Storage and Disposal Instructions

Storage and disposal of Imperan (Metoclopramide) must adhere strictly to the conditions specified in official regulatory labeling.

Storage Requirements:

Imperan must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, which should be tightly closed, to protect the contents from light and moisture. The injection solution should not be frozen, as directed in the prescribing information. All forms must be stored out of the sight and reach of children.

Disposal Protocol:

Unused or expired Imperan must be disposed of in accordance with local regulations. Medicines should not be disposed of via household wastewater or trash, especially if a medication take-back program is available in the community. If no take-back program exists, specific instructions for safe household disposal may apply.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imperan found in:

A-Z Index: